- Home
- COLL vs LILAK Comparison
COLL vs LILAK Comparison
Compare COLL & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- LILAK
- Stock Information
- Founded
- COLL 2002
- LILAK 2017
- Country
- COLL United States
- LILAK Bermuda
- Employees
- COLL N/A
- LILAK N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- LILAK Cable & Other Pay Television Services
- Sector
- COLL Health Care
- LILAK Telecommunications
- Exchange
- COLL Nasdaq
- LILAK Nasdaq
- Market Cap
- COLL 958.8M
- LILAK 1.1B
- IPO Year
- COLL 2015
- LILAK N/A
- Fundamental
- Price
- COLL $38.32
- LILAK $8.17
- Analyst Decision
- COLL Strong Buy
- LILAK Hold
- Analyst Count
- COLL 4
- LILAK 2
- Target Price
- COLL $44.25
- LILAK $7.85
- AVG Volume (30 Days)
- COLL 427.8K
- LILAK 1.8M
- Earning Date
- COLL 08-07-2025
- LILAK 11-05-2025
- Dividend Yield
- COLL N/A
- LILAK N/A
- EPS Growth
- COLL N/A
- LILAK N/A
- EPS
- COLL 1.06
- LILAK N/A
- Revenue
- COLL $707,007,000.00
- LILAK $4,409,700,000.00
- Revenue This Year
- COLL $22.23
- LILAK $1.21
- Revenue Next Year
- COLL $2.78
- LILAK $2.90
- P/E Ratio
- COLL $36.58
- LILAK N/A
- Revenue Growth
- COLL 22.61
- LILAK N/A
- 52 Week Low
- COLL $23.23
- LILAK $4.23
- 52 Week High
- COLL $42.29
- LILAK $10.67
- Technical
- Relative Strength Index (RSI)
- COLL 59.51
- LILAK 64.53
- Support Level
- COLL $38.00
- LILAK $7.94
- Resistance Level
- COLL $39.78
- LILAK $8.30
- Average True Range (ATR)
- COLL 0.97
- LILAK 0.25
- MACD
- COLL -0.18
- LILAK -0.05
- Stochastic Oscillator
- COLL 38.72
- LILAK 68.04
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.